Comparative Pharmacology
Head-to-head clinical analysis: ESTROSTEP FE versus LOESTRIN 21 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROSTEP FE versus LOESTRIN 21 1 5 30.
ESTROSTEP FE vs LOESTRIN 21 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive